

## REFERENCES

1. Calame K, Lin KI, and Tunyaplin C. Regulatory mechanism that determine the development and function of plasma cells. *Annu Rev Immunol.* 2003; 21: 205-30.
2. Kallies A and Nutt SL. Terminal differentiation of lymphocytes depends on Blimp 1. *Cur Opin Immunol* 2007; 19: 156-62.
3. Lin KI, Duclos CA, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cell to immunoglobulin M-secreting plasma cells. *Mol Cell Biol.* 2002; 22: 4771-80.
4. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. *Immunol cell Biol.* 2008; 86: 47-53.
5. Shelef SM, Lin KI, Williams Mc, Liao J, Williams MGM, and Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. *Immunity.* 2003; 19: 607-20.
6. Lin KI, Tunyaplin C, Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. *Immunol Rev.* 2003; 194: 19-28.

7. Martins G, Calame K. Regulation and Functions of Blimp-1 in T and B lymphocytes. *Annu Rev Immunol.* 2008; 26: 133-69
8. Tunyaplin C, Shapiro MA, Calame K. Characterization of the B lymphocyte-induced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter. *Nucleic Acids Res.* 2000; 28: 4846-55.
9. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. *Br J Haematol.* 2002; 116: 429-35.
10. Nilsson J, Söderberg O, Nilsson K, Rosén A. Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. *Immunol Lett.* 2004; 15: 83-9.
11. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. *Immunity.* 2004; 21: 81-93.
12. Nakase K, Ishimaru F, Fujii K, Tabayashi T, Kozuka T, Sezaki N, et al. Overexpression of novel short isoforms of Helios in a patient with T-cell acute lymphoblastic leukemia. *Exp Hematol.* 2002; 30: 313-7.

13. Tabayashi T, Ishimaru F, Takata M, Kataoka I, Nakase K, Kozuka T, et al.  
Characterization of the short isoform of Helios overexpressed in patients with T-cell malignancies. *Cancer Sci.* 2007 Feb; 98(2):182-8.
14. Györy I, Fejér G, Ghosh N, Seto E and Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. *J Immunol*, 2003, 170: 3125-3133.
15. Keller AD and Maniatis T. Identification and characterization of a novel repression of beta-interferon gene expression. *Gene*. 1991; 5: 868-79.
16. Turner CA, Jr Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell*. 1994; 77: 297-306.
17. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. *J Exp Med*. 2004; 200: 967
18. Calame K. Transcriptional factors that regulate memory in humoral responses. *Immunol Rev*. 2006; 211: 269-79.

19. Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, McKenzie BS, et al.  
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. *Immunity*, 2007; 26: 555-566.
20. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. *Science*. 1997; 276: 596-9.
21. Sciammas R, Davis MM. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. *J Immunol*. 2004; 172: 5427-40.
22. Tooze RM, Stephenson S and Doody GM. Repression of IFN- $\gamma$  Induction of Class II Transactivator: A Role for PRDM1/Blimp-1 in regulation of cytokine signaling. *J Immunol*, 2006, 177: 4584-4593.
23. Piskurich JF, Lin KI, Lin Y, Wang, Ting JPY, Calame K. BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells. *Nat Immunol*. 2000; 1: 526-32.
24. Buckland J. B-cell Development: BLIMP-1, BCL-6 and B-cell fate. *Nat Rev Immunol*. 2002;2: 629
25. Johnson K, Shelef MS, Tunyaplin C, Calame K. Regulatory events in early and late B cell differentiation. *Mol Immunol*. 2005; 42: 749-61.

26. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald, A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*. 2002; 17: 51-62.
27. Marker KW and Wilson CB. Sound of a silent Blimp-1. *Nat Immunol*. 2004; 5: 241-2.
28. Northrup DL and Allman D. Transcriptional regulation of early B cell development. *Immunol Res*. 2008; 42: 106-17.
29. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. *Mol Cell Biol*. 2000; 20: 2592-603.
30. Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. *Nat Immunol*. 2004; 5: 299-308.
31. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. *Cancer Cell*. 2007; 11: 349-60.

31. Giorgio C, Cristina AD, Rita S, Zhou H, Wang D, Bachir A. PRDMI/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. *Pathology*. 2005; 206: 76-86.
32. Schmidt D, Nayak A, Schumann JE, Schimpl A, Berberich I, Berberich-Siebelt F. Blimp-1 $\Delta$ 7: A naturally occurring Blimp-1 deletion mutant with auto-regulatory potential. *Exp Cell Res*. 2008; 314: 3614-3627.
33. Petsophonsakul W, Kaewrakmuk, J, Punyot, M, Charoenkwan P and Nawarawong. Expression of Blimp-1 transcription factors mRNA isoforms in mononuclear cells from bone marrow of leukemia and lymphoma patients. The 13<sup>th</sup> International congress of immunology, Rio de Janeiro-Brazil, August 21-25, 2007.
34. Shapiro-Shelef M, Lin-I K, Savitsky D, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. *J Exp Med* 2005; 202(11): 1471-76.